Please login to the form below

oncolytic viruses

This page shows the latest oncolytic viruses news and features for those working in and with pharma, biotech and healthcare.

Boehringer bolts on another immuno-oncology company

The company currently has clinical-phase projects ranging across checkpoint inhibitors, oncolytic viruses, cancer vaccines and T-cell engagers, with around half of its early-to-mid-stage pipeline emerging from ... 2006. Other oncolytic virus candidates

Latest news

Vyriad inks immunotherapy alliance with Merck/Pfizer

Oncolytic viruses are engineered to selectively replicate within and destroy cancer cells while simultaneously augmenting anti-tumour immunity, and are generally injected directly into tumour sites. ... There’s a lot of activity going on in R&D however,
J&J pays $140m upfront for cancer-busting virus firm BeneVir

that the promise of oncolytic viruses will come to fruition when they are used in combination with other cancer immunotherapies. ... The biotech’s website indicates that its oncolytic viruses lend themselves to co-administration with immune checkpoint
Sanofi’s latecomer PD-1 gets date for FDA verdict

and oncolytic viruses.
Boehringer buys into oncolytic viruses via €210m ViraTherapeutics deal

Boehringer buys into oncolytic viruses via 210m ViraTherapeutics deal. Option to acquire the Austrian biotech after phase I trials remains open to Boehringer . ... The deal - valued at up to 210m ($236m) - gives Boehringer joint development rights to
BMS to explore new options for its immuno-oncology drug Opdivo

Jean Viallet, global clinical research lead for oncology at BMS, said: “ This collaboration continues to expand our clinical development of Opdivo and explores how oncolytic viruses may provide a complementary mechanism

More from news
Approximately 2 fully matching, plus 8 partially matching documents found.

Latest Intelligence

Cancer immunotherapy: What's on the horizon?

cell-based therapies and oncolytic viruses that attack malignant cells directly, and cancer vaccines that try to kickstart an intrinsic immune reaction to the tumour. ... Oncolytic viruses. An oncolytic virus is a virus that preferentially infects and
Gene therapy

From a payload perspective, these include new technologies such as siRNA, Sleeping Beauty transposases, CRISPR-Cas9 gene editing, ARCUS gene editing, nucleic acid vaccines, oncolytic viruses and chemically modified mRNA. ... In contrast, viruses still
Deal Watch December 2016

995+. PsiOxus Therapeutics (UK). BMS (US). Licence. NG-348: preclinical “ armed” oncolytic virus targeting tumour cells. ... technology in the development of immunomodulatory oncolytic viruses.
The Maverick: giving medicines away free

His fundamental idea is to create synthetic viruses that can invade cancer cells, destroy them, and then multiply into more viruses to kill the remaining cancerous cells. ... This forms part of a new research area known as oncolytic virology that uses

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

Turnstone Biologics bolsters leadership team

Oncolytic viruses and cancer vaccines have the potential to benefits a wide range of patients living with cancer, and the company’s proprietary viral platform technology is at the forefront of ... we advance clinical development of our next-generation

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Products as portfolios: positioning immuno-oncology products

In addition, developments in oncolytic viruses mean the options for patients with certain solid tumours are ever-expanding.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Graduate Scientific Editor: DOE

Account Manager, Healthcare Advertising: £30 - 38, 000 (or -)

Senior Writer, Healthcare Advertising, London: Excellent package

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Healthcare PR Senior Account Manager: Salary TBC

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Integrated Brand/ Digital Senior Account Director, London: Excellent package

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Healthcare PR Director: £100, 000 – £120, 000 benefits

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Account Manager: Negotiable

Systematic Review Lead- London: Negotiable

Medical Writer - Creative and Scientific Projects: DOE

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Market Access Consultant - Greater Manchester: Negotiable

Senior Medical Writer: Salary is DOE

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Associate Scientific Director: Salary TBC

Deputy Managing Director – Healthcare PR – Global Agency: Negotiable

Senior Account Manager – Healthcare Advertising: Salary TBC

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Subscribe to our email news alerts

PMHub

Add my company

Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....